Copyright investors
One important metric to look for in a stock is an 80 or higher Relative Strength Rating. Spyre Therapeutics (SYRE) now clears that threshold, with a jump from 80 to 85 Tuesday. This exclusive rating from Investor's Business Daily identifies market leadership with a 1 (worst) to 99 (best) score. The score shows how a stock's price movement over the last 52 weeks holds up against all the other stocks in our database. Decades of market research reveals that the best stocks often have an RS Rating north of 80 as they begin their biggest price moves. Spyre Therapeutics is now considered extended and out of buy range after clearing an 11.35 buy point in a third-stage consolidation. See if the stock forms a new pattern or follow-on buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week moving average. The company posted 0% earnings growth in the latest quarterly report. Sales rose -100%. Look for the next report on or around Nov. 6. Spyre Therapeutics holds the No. 134 rank among its peers in the Medical-Biomed/Biotech industry group. argenx ADR (ARGX), Aurinia Pharmaceuticals (AUPH) and Halozyme Therapeutics (HALO) are among the top 5 highly rated stocks within the group. This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
